Page 10 - Clinical Trial Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Investegate announcements from Redx Pharma plc, RXC004 Topline Data From a Phase 2 Module

Dupixent® (dupilumab) application for treatment of chronic spontaneous urticaria (CSU) in adults and adolescents accepted for FDA review More than 300,000 people in the U.S. suffer

ReCor Medical Announces Consistent Reduction of Blood Pressure in Pooled Analysis of Three Clinical Trials at AHA 2022 - read this article along with other careers information, tips and advice on BioSpace

Compiled Data from RADIANCE Global Program Show Consistent Treatment Effect and Safety Across Broad Patient PopulationPALO ALTO, Calif.--(BUSINESS WIRE)--ReCor Medical, Inc. (“ReCor”) and its parent company, Otsuka Medical Devices Co., Ltd. today announced consistent and significant blood pressure (“BP”) lowering re...

Results add to the growing body of evidence and reinforce the efficacy profile of Sotyktu, a once-daily, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of moderate-to-severe plaque psoriasisNew analysis to be presented at the 2022 European Academy of Dermatology and Venereology Cong...